江苏吴中:AestheFill(艾塑菲)中国境内代理权相关事项存在一定的不确定性
Core Viewpoint - Jiangsu Wuzhong (600200) has issued a risk alert regarding the potential equity transfer of its partner in the medical aesthetics product AestheFill, while maintaining its exclusive agency rights in China until August 28, 2032 [1] Group 1: Company Information - The exclusive agency rights for AestheFill in China remain unchanged, and sales are proceeding normally [1] - AestheFill generated sales revenue of 195 million yuan in the first three quarters of 2024, accounting for 11.86% of the company's total operating income [1] - The company is actively communicating with Regen Biotech, Inc. and related parties regarding the sustainability of its agency rights in China, acknowledging potential uncertainties [1]